Ennov is proud to announce the successful integration of the Enterprise Technology division from Calyx into our organization. This strategic acquisition, completed on June 1, 2024, significantly enhances Ennov’s portfolio by incorporating the advanced eClinical and eRegulatory solutions that Enterprise Technology is known for, including the highly regarded Liquent InSight as well as IMPACT and DataLabs solutions.
Expanding Our Global Footprint
With this acquisition, Ennov’s established presence in Europe, North America, and Southeast Asia is now complemented by Calyx’s strong foothold in the United States, the United Kingdom, and India, creating a powerful global network. Over the past few months, our teams have discovered a strong alignment in company culture, as well as the ability to streamline our corporate operations. This expanded presence enhances our ability to serve clients worldwide, providing innovative solutions and comprehensive support.
Ennov now gains a stronger footprint in the US and the UK, leading to a balanced group with increased strength in the North American and European markets. Ennov employs over 400 highly skilled professionals across nine locations in the US, Europe, and Asia, ensuring global reach and support. Calyx Enterprise Technology has a proven track record, having supported over 60,000 studies involving more than 140,000 patients and has carried out over one million global regulatory submissions. Their services are highly regarded among large pharmaceutical companies, mid-sized biotechnology firms, and CROs, primarily in North America and Europe.
“This acquisition enhances both our capabilities and our international footprint. By combining our expertise, we are better equipped to address the evolving demands of the life sciences sector, serving everything from small biotech firms to major pharmaceutical and medical device companies across the entire product development lifecycle.”
Olivier Pâris, President of Ennov
Innovating Together for a Brighter Future
The integration of Ennov and Enterprise Technology brings together extensive industry knowledge and regulatory expertise, fostering the creation of new and innovative solutions. This partnership is set to provide our clients with enhanced capabilities to navigate compliance challenges confidently. Together, we will continue to innovate and deliver exceptional value to our clients in the life sciences industry.
This acquisition aligns perfectly with Ennov’s mission to deliver the only unified and cost-effective cloud-based compliance platform for life sciences organizations. The expanded suite now includes advanced solutions for quality management, regulatory affairs, drug safety, clinical studies, and transparency management. Ennov will seamlessly integrate Calyx Enterprise Technology into its operations, ensuring a smooth transition for all customers and employees.
About Calyx
Through innovative eClinical solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market faster. With deep expertise in clinical development and more than 25 years of supporting trial sponsors and clinical research organizations (CROs), Calyx harnesses that intelligence and activates its potential to solve complex problems, deliver fast insights, and get new drugs to market every day.
